ReviewInternational journal of molecular sciences2021
Towards Biomanufacturing of Cell-Derived Matrices.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Advances in cell-derived extracellular matrix for 3D tumor modelling.Materials today. Bio · 2026Review
- High-yield cell-derived extracellular matrix bioink via macromolecular crowding for versatile 3D bioprinting.Materials today. Bio · 2026Article
- Recent advances in applications of nanoparticles and decellularized ECM for organoid engineering.Materials today. Bio · 2025Review
- Synthetic scaffolds functionalized with mesenchymal stem/stromal cells-derived extracellular matrix for bone tissue engineering: a review.RSC advances · 2025Review
- Abnormal iron metabolism in the zona incerta in Parkinson's disease mice.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Advances in abiotic tissue-based biomaterials: A focus on decellularization and devitalization techniques.Materials today. Bio · 2025Article
- Rescue of mitochondrial dysfunction through alteration of extracellular matrix composition in barth syndrome cardiac fibroblasts.Biomaterials · 2025Article
- Nanomechanics of cell-derived matrices as a functional read-out in collagen VI-related congenital muscular dystrophies.Journal of the Royal Society, Interface · 2025Article
- In Vitro Engineered ECM-incorporated Hydrogels for Osteochondral Tissue Repair: A Cell-Free Approach.Advanced healthcare materials · 2025Article
- Macromolecular Crowding for Reparative Medicine and Drug Discovery Applications.Sub-cellular biochemistry · 2025Review
- The considerations on selecting the appropriate decellularized ECM for specific regeneration demands.Materials today. Bio · 2024Review
- [Advantages and prospects of cell derived decellularized extracellular matrix as tissue engineering scaffolds].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2024Review
- Engineering cell-derived extracellular matrix for peripheral nerve regeneration.Materials today. Bio · 2024Review
- The importance of 3D fibre architecture in cancer and implications for biomaterial model design.Nature reviews. Cancer · 2024Review
- Review
- Cell-Derived Matrix: Production, Decellularization, and Application of Wound Repair.Stem cells international · 2024Review
- Recent advances in the crosstalk between adipose, muscle and bone tissues in fish.Frontiers in endocrinology · 2023Review
- Innovative bioinks for 3D bioprinting: Exploring technological potential and regulatory challenges.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Cell-derived matrices (CDM) are the decellularised extracellular matrices (ECM) of tissues obtained by the laboratory culture process. CDM is developed to mimic, to a certain extent, the properties of the needed natural tissue and thus to obviate the use of animals. The composition of CDM can be tailored for intended applications by carefully optimising the cell sources, culturing conditions and decellularising methods. This unique advantage has inspired the increasing use of CDM for biomedical research, ranging from stem cell niches to disease modelling and regenerative medicine. However, while much effort is spent on extracting different types of CDM and exploring their utilisation, little is spent on the scale-up aspect of CDM production. The ability to scale up CDM production is essential, as the materials are due for clinical trials and regulatory approval, and in fact, this ability to scale up should be an important factor from the early stages. In this review, we first introduce the current CDM production and characterisation methods. We then describe the existing scale-up technologies for cell culture and highlight the key considerations in scaling-up CDM manufacturing. Finally, we discuss the considerations and challenges faced while converting a laboratory protocol into a full industrial process. Scaling-up CDM manufacturing is a challenging task since it may be hindered by technologies that are not yet available. The early identification of these gaps will not only quicken CDM based product development but also help drive the advancement in scale-up cell culture and ECM extraction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.